Publisher Health

This post was originally published on this site

One in five adults said they experienced any symptoms of anxiety or depression in a 2-week period, according to a 2022 CDC survey.

The FDA added a warning to the label of esketamine nasal spray (Spravato), noting that long-term cognitive and memory impairments have been reported with ketamine misuse or abuse.

Ketamine was detected in less than 1% of overdose deaths in the U.S., a 2019-2023 analysis found. (Morbidity and Mortality Weekly Report)

Why did lithium fall out of favor for bipolar disorder? (The Guardian)

Greater depression severity was significantly associated with increased diabetes incidence and elevated HbA1c, fasting glucose, and insulin levels, an analysis of national survey data found. (Scientific Reports)

Over the past 50 years, the prevalence of antipsychotic polypharmacy increased globally and was tied to increased risks of relapse, psychiatric hospitalization, and worse global functioning versus monotherapy. (Lancet Psychiatry)

Investigational emraclidine flopped in two phase II studies, failing to reduce symptom severity in adults with schizophrenia who were experiencing an acute exacerbation of psychotic symptoms, said developer AbbVie.

College students in sexual and gender minority groups were more likely to report depression, a survey study showed. (Journal of American College Health)

Autism spectrum disorder diagnoses increased 175% from 2011 to 2022, and are becoming more prevalent in young adults, according to a cross-sectional study. (JAMA Network Open)

A psychiatrist explains the difference between “normal” anxiety and an anxiety disorder. (Washington Post)

Brief cognitive behavioral therapy by video telehealth reduced suicide attempts among adults with recent suicidal ideation or behavior in a randomized trial. (JAMA Network Open)

BioXcel said a phase III at-home trial testing its investigational drug for agitation associated with bipolar disorders, schizophrenia, and Alzheimer’s dementia is now underway.

The Canadian Research Initiative in Substance Matters released a guideline update for the clinical management of opioid use disorder, recommending buprenorphine and methadone as first-line treatments. (CMAJ)

Increasing alcohol use during the COVID pandemic persisted into 2022, a national cross-sectional study showed. (Annals of Internal Medicine)